Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
1.
PLoS One ; 16(6): e0253048, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34111207

RESUMEN

BACKGROUND: Little is known about the prevalence and best management of needle fear in adults with chronic disease, who may experience frequent and long-term exposure to needles for lifesaving therapies such as renal dialysis and cancer treatment. Identifying interventions that assist in management of needle fear and associated distress is essential to support these patients with repeated needle and cannula exposure. METHOD: We followed the PRISMA methodology for scoping reviews and systematically searched PsychINFO, PubMed (MEDLINE), ProQuest, Embase and grey literature and reference lists between 1989 and October 2020 for articles related to needle discomfort, distress, anxiety, fear or phobia. The following chronic diseases were included: arthritis, asthma, chronic back pain, cancer, cardiovascular disease, chronic obstructive pulmonary disease, diabetes, and mental illness, or kidney failure. Literature concerning dentistry, vaccination, intravenous drug users and paediatric populations were excluded. RESULTS: We identified 32 papers reporting prevalence (n = 24), management (n = 5) or both (n = 3). Needle fear prevalence varied in disease cohorts: 17-52% (cancer), 25-47% (chronic kidney disease) and 0.2-80% (diabetes). Assessment methods varied across studies. Management strategies had poor evidence-base, but included needle-specific education, decorated devices, cognitive-behavioural stress management techniques, distraction, and changing the therapy environment or modality. CONCLUSION: Although needle fear is common there is a paucity of evidence regarding interventions to address it among adults living with chronic disease. This scoping review has highlighted the need for improved identification of needle fear in adults and development of interventions are required for these cohorts.


Asunto(s)
Enfermedad Crónica/psicología , Trastornos Fóbicos/epidemiología , Trastornos Fóbicos/terapia , Adulto , Enfermedad Crónica/clasificación , Terapia Cognitivo-Conductual , Manejo de la Enfermedad , Medicina Basada en la Evidencia , Humanos , Trastornos Fóbicos/psicología , Prevalencia
2.
Int J Mol Sci ; 19(9)2018 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-30200383

RESUMEN

Green cincau (Premna oblongifolia Merr.) is a traditional food of Indonesia and provides a natural source of dietary fibre and antioxidants. This study evaluated the ability of green cincau, and other dietary fibres with or without the addition of anti-oxidant, epigallocatechin-3-gallate (EGCG), to prevent colorectal cancer in a 12 week azoxymethane (AOM) rat model. While all dietary treatments stimulated short chain fatty acid production (SCFA) in the digesta and faeces, no one treatment was able to significantly protect against aberrant crypt formation (ACF), when compared to the control diet. However, feeding green cincau leaves or extracts did not result in an increase in ACF compared to the control diet. Unexpectedly, when the dietary fibre source was pectin, 0.1% EGCG increased proliferative activity and liver lipid peroxidation when compared to the control diet containing cellulose. Examination of faecal microbial communities identified the presence of short chain acid producing bacteria, but a distinct community profile was not observed from any individual diet group. Overall, this research implies that combining dietary fibre with an antioxidant does not automatically equate to a beneficial response. Further work is required to investigate the health-promoting properties of green cincau.


Asunto(s)
Neoplasias del Colon/prevención & control , Fibras de la Dieta/uso terapéutico , Ácidos Grasos Volátiles/metabolismo , Lamiaceae/química , Animales , Azoximetano/toxicidad , Células Cultivadas , Colon/efectos de los fármacos , Colon/metabolismo , Colon/microbiología , Neoplasias del Colon/etiología , Fibras de la Dieta/farmacología , Microbioma Gastrointestinal , Peroxidación de Lípido , Masculino , Ratas , Ratas Sprague-Dawley
3.
Mol Nutr Food Res ; 62(17): e1800080, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-29889351

RESUMEN

SCOPE: Dietary supplementation with polyphenol-rich propolis can protect against experimentally induced colitis. We examined whether different polyphenol compositions of Chinese propolis (CP) and Brazilian propolis (BP) influence their ability to protect against dextran sulfate sodium (DSS)-induced colitis in rats. METHODS AND RESULTS: HPLC-DAD/Q-TOF-MS analysis confirmed that polyphenol compositions of CP and BP were dissimilar. Rats were given CP or BP by gavage (300 mg kg-1 body weight) throughout the study, starting 1 week prior to DSS treatment for 1 week followed by 3 d without DSS. CP and BP significantly reduced the colitis disease activity index relative to controls not receiving propolis, prevented significant DSS-induced colonic tissue damage, and increased resistance to DSS-induced colonic oxidative stress as shown by reduced malonaldehyde levels and increased T-AOC levels. CP and BP significantly reduced DSS-induced colonic apoptosis. Colonic inflammatory markers IL-1ß, IL-6, and MCP-1 were suppressed by CP and BP, whereas only BP-induced expression of TGF-ß. CP, not BP, increased the diversity and richness of gut microbiota populations. Both forms of propolis significantly reduced populations of Bacteroides spp. CONCLUSIONS: Despite the dissimilar polyphenol compositions of CP and BP, their ability to protect against DSS-induced colitis is similar. Nevertheless, some different physiological impacts were observed.


Asunto(s)
Bacteroides/efectos de los fármacos , Colitis/tratamiento farmacológico , Microbioma Gastrointestinal/efectos de los fármacos , Própolis/química , Própolis/farmacología , Animales , Brasil , China , Colitis/inducido químicamente , Colitis/genética , Colon/efectos de los fármacos , Colon/microbiología , Colon/patología , Sulfato de Dextran/toxicidad , Modelos Animales de Enfermedad , Microbioma Gastrointestinal/genética , Regulación de la Expresión Génica/efectos de los fármacos , Masculino , Estrés Oxidativo/efectos de los fármacos , Ratas Sprague-Dawley
4.
Integr Cancer Ther ; 17(2): 248-262, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-28381120

RESUMEN

The acute apoptotic response to genotoxic carcinogens animal model has been extensively used to assess the ability of drugs and natural products like dietary components to promote apoptosis in the colon and protect against colorectal cancer (CRC). This work aimed to use this model to identify the main chemopreventative agent in extracts from an Australian mollusc Dicathais orbita, while simultaneously providing information on their potential in vivo toxicity. After 2 weeks of daily oral gavage with bioactive extracts and purified brominated indoles, mice were injected with the chemical carcinogen azoxymethane (AOM; 10 mg/kg) and then killed 6 hours later. Efficacy was evaluated using immunohistochemical and hematoxylin staining, and toxicity was assessed via hematology, blood biochemistry, and liver histopathology. Comparison of saline- and AOM-injected controls revealed that potential toxic side effects can be interpreted from blood biochemistry and hematology using this short-term model, although AOM negatively affected the ability to detect histopathological effects in the liver. Purified 6-bromoisatin was identified as the main cancer preventive agent in the Muricidae extract, significantly enhancing apoptosis and reducing cell proliferation in the colonic crypts at 0.05 mg/g. There was no evidence of liver toxicity associated with 6-bromoisatin, whereas 0.1 mg/g of the brominated indole tyrindoleninone led to elevated aspartate aminotransferase levels and a reduction in red blood cells. As tyrindoleninone is converted to 6-bromoisatin by oxidation, this information will assist in the optimization and quality control of a chemopreventative nutraceutical from Muricidae. In conclusion, preliminary data on in vivo safety can be simultaneously collected when testing the efficacy of new natural products, such as 6-bromoisatin from Muricidae molluscs for early stage prevention of colon cancer.


Asunto(s)
Neoplasias del Colon/prevención & control , Indoles/efectos adversos , Indoles/farmacología , Moluscos/química , Animales , Apoptosis/efectos de los fármacos , Australia , Carcinógenos/farmacología , Proliferación Celular/efectos de los fármacos , Quimioprevención/métodos , Neoplasias del Colon/inducido químicamente , Hidrocarburos Bromados/efectos adversos , Hidrocarburos Bromados/farmacología , Isatina/efectos adversos , Isatina/análogos & derivados , Isatina/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL
5.
Nutrients ; 9(4)2017 04 03.
Artículo en Inglés | MEDLINE | ID: mdl-28368356

RESUMEN

Green cincau (Premna oblongifolia Merr) is an Indonesian food plant with a high dietary fibre content. Research has shown that dietary fibre mixtures may be more beneficial for colorectal cancer prevention than a single dietary fibre type. The aim of this study was to investigate the effects of green cincau extract on short chain fatty acid (SCFA) production in anaerobic batch cultures inoculated with human faecal slurries and to compare these to results obtained using different dietary fibre types (pectin, inulin, and cellulose), singly and in combination. Furthermore, fermentation supernatants (FSs) were evaluated in Caco-2 cells for their effect on cell viability, differentiation, and apoptosis. Cincau increased total SCFA concentration by increasing acetate and propionate, but not butyrate concentration. FSs from all dietary fibre sources, including cincau, reduced Caco-2 cell viability. However, the effects of all FSs on cell viability, cell differentiation, and apoptosis were not simply explainable by their butyrate content. In conclusion, products of fermentation of cincau extracts induced cell death, but further work is required to understand the mechanism of action. This study demonstrates for the first time that this Indonesian traditional source of dietary fibre may be protective against colorectal cancer.


Asunto(s)
Anticarcinógenos/metabolismo , Apoptosis , Neoplasias del Colon/prevención & control , Fibras de la Dieta/metabolismo , Microbioma Gastrointestinal , Extractos Vegetales/metabolismo , Prebióticos , Anticarcinógenos/aislamiento & purificación , Células CACO-2 , Diferenciación Celular , Supervivencia Celular , Celulosa/metabolismo , Neoplasias del Colon/metabolismo , Neoplasias del Colon/microbiología , Neoplasias del Colon/patología , Ácidos Grasos Volátiles/metabolismo , Heces/microbiología , Fermentación , Bacterias Aerobias Gramnegativas/crecimiento & desarrollo , Bacterias Aerobias Gramnegativas/aislamiento & purificación , Bacterias Aerobias Gramnegativas/metabolismo , Bacterias Grampositivas/crecimiento & desarrollo , Bacterias Grampositivas/aislamiento & purificación , Bacterias Grampositivas/metabolismo , Humanos , Indonesia , Inulina/metabolismo , Lamiaceae/química , Pectinas/metabolismo , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Hojas de la Planta/química , Prebióticos/análisis
6.
Br J Nutr ; 116(11): 1901-1911, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27923410

RESUMEN

Se and green tea have been shown in epidemiological, observational and preclinical studies to be inversely related to the risk of developing colorectal cancer (CRC). However, there are limited studies to evaluate their regulatory effects on genes/proteins that relate to CRC oncogenesis in human subjects, such as selenoproteins, WNT signalling pathway, inflammation and methylation. This study examined the effects of supplementation of Se using Brazil nuts and green tea extract (GTE) capsules, alone and in combination, on targeted biomarkers. In total, thirty-two volunteers (>50 years of age) with plasma Se≤1·36 µmol/l were randomised to one of three treatment groups: nine to Se (approximately 48 µg/d) as six Brazil nuts, eleven to four GTE capsules (800 mg (-)-epigallocatechin-3-gallate) and twelve to a combination of Brazil nuts and GTE. Blood and rectal biopsies were obtained before and after each intervention. Plasma Se levels, rectal selenoprotein P (SePP) and ß-catenin mRNA increased significantly in subjects consuming Brazil nuts alone or in combination, whereas rectal DNA methyltransferase (DNMT1) and NF-κB mRNA were reduced significantly in subjects consuming GTE alone or in combination. None of the interventions significantly affected rectal acetylated histone H3 or Ki-67 expression at the protein level or plasma C-reactive protein. Effects of the combination of Brazil nuts and GTE did not differ from what would be expected from either agent alone. In conclusion, supplementation of Brazil nuts and/or GTE regulates targeted biomarkers related to CRC oncogenesis, specifically genes associated with selenoproteins (SePP), WNT signalling (ß-catenin), inflammation (NF-κB) and methylation (DNMT1). Their combination does not appear to provide additional effects compared with either agent alone.


Asunto(s)
Anticarcinógenos/uso terapéutico , Bertholletia , Camellia sinensis/química , Neoplasias Colorrectales/prevención & control , Suplementos Dietéticos , Nueces , Extractos Vegetales/uso terapéutico , Anciano , Bertholletia/efectos adversos , Bertholletia/química , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/metabolismo , Neoplasias Colorrectales/epidemiología , Neoplasias Colorrectales/metabolismo , Neoplasias Colorrectales/patología , Suplementos Dietéticos/efectos adversos , Estudios de Factibilidad , Femenino , Manipulación de Alimentos , Alimentos Funcionales/efectos adversos , Humanos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Masculino , Persona de Mediana Edad , Nueces/efectos adversos , Nueces/química , Extractos Vegetales/efectos adversos , Extractos Vegetales/química , Hojas de la Planta/química , Recto/metabolismo , Recto/patología , Riesgo , Selenio/administración & dosificación , Selenio/efectos adversos , Selenio/sangre , Selenio/uso terapéutico , Australia del Sur/epidemiología
7.
Nutr Res ; 36(9): 982-988, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27632918

RESUMEN

O(6)-methyl guanine (O(6)MeG) adducts are major toxic, promutagenic, and procarcinogenic adducts involved in colorectal carcinogenesis. Resistant starch and its colonic metabolite butyrate are known to protect against oncogenesis in the colon. In this study, we hypothesized that a dietary intervention that specifically delivers butyrate to the large bowel (notably butyrylated high-amylose maize starch [HAMSB]) would reduce colonic levels of O(6)MeG in rats shortly after exposure to the deoxyribonucleic acid (DNA) alkylating agent azoxymethane (AOM) when compared with a low-amylose maize starch (LAMS). A further objective was to validate an immunohistochemistry (IHC) method for quantifying O(6)MeG against a high-performance liquid chromatography method using fluorescence and diode array detection. Rats were fed either LAMS or HAMSB diets for 4 weeks followed by a single injection of AOM or saline and killed 6 hours later. After AOM exposure, both IHC and high-performance liquid chromatography method using fluorescence and diode array detection measured a substantially increased quantity of DNA adducts in the colon (P<.001). Both techniques demonstrated equally that consumption of HAMSB provided a protective effect by reducing colonic adduct load compared with the LAMS diet (P<.05). In addition, IHC allowed visualization of the O(6)MeG distribution, where adduct load was reduced in the lower third of the crypt compartment in HAMSB-fed rats (P=.036). The apoptotic response to AOM was higher in the HAMSB-fed rats (P=.002). In conclusion, the reduction in O(6)MeG levels and enhancement of the apoptotic response to DNA damage in the colonic epithelium through consumption of HAMSB provide mechanistic insights into how HAMSB protects against colorectal tumorigenesis.


Asunto(s)
Amilosa/farmacología , Azoximetano/efectos adversos , Butiratos/metabolismo , Colon/efectos de los fármacos , Aductos de ADN/metabolismo , Dieta , Guanina/análogos & derivados , Amilosa/metabolismo , Animales , Carcinógenos , Cromatografía Líquida de Alta Presión , Colon/metabolismo , Guanina/metabolismo , Inmunohistoquímica , Masculino , Ratas Sprague-Dawley
8.
Carcinogenesis ; 37(4): 366-375, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26905582

RESUMEN

This study evaluated whether dietary resistant starch (RS) and green tea extract (GTE), which have anti-inflammatory and anticancer properties, protect against colitis-associated colorectal cancer (CAC) using a rat model, also investigated potential mechanisms of action of these agents including their effects on the gut microbiota. Rats were fed a control diet or diets containing 10% RS, 0.5% GTE or a combination of the two (RS + GTE). CAC was initiated with 2 weekly azoxymethane (AOM) injections (10mg/kg) followed by 2% dextran sodium sulphate in drinking water for 7 days after 2 weeks on diets. Rats were killed 20 weeks after the first AOM. Colon tissues and tumours were examined for histopathology by H&E, gene/protein expression by PCR and immunohistochemistry and digesta for analyses of fermentation products and microbiota populations. RS and RS + GTE (but not GTE) diets significantly (P< 0.05) decreased tumour multiplicity and adenocarcinoma formation, relative to the control diet. Effects of RS + GTE were not different from RS alone. RS diet caused significant shifts in microbial composition/diversity, with increases in Parabacteroides, Barnesiella, Ruminococcus, Marvinbryantia and Bifidobacterium as primary contributors to the shift. RS-containing diets increased short chain fatty acids (SCFA) and expression of the SCFA receptor GPR43 mRNA, and reduced inflammation (COX-2, NF-kB, TNF-α and IL-1ß mRNA) and cell proliferation P< 0.05. GTE had no effect. This is the first study that demonstrates chemopreventive effects of RS (but not GTE) in a rodent CAC model, suggesting RS might have benefit to patients with ulcerative colitis who are at an increased risk of developing CRC.


Asunto(s)
Colitis/prevención & control , Neoplasias Colorrectales/prevención & control , Intestinos/microbiología , Almidón/metabolismo , Animales , Colitis/complicaciones , Colitis/microbiología , Ratas
9.
Br J Nutr ; 114(2): 220-30, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26084032

RESUMEN

Epidemiological studies have identified increased colorectal cancer (CRC) risk with high red meat (HRM) intakes, whereas dietary fibre intake appears to be protective. In the present study, we examined whether a HRM diet increased rectal O(6)-methyl-2-deoxyguanosine (O(6)MeG) adduct levels in healthy human subjects, and whether butyrylated high-amylose maize starch (HAMSB) was protective. A group of twenty-three individuals consumed 300 g/d of cooked red meat without (HRM diet) or with 40 g/d of HAMSB (HRM+HAMSB diet) over 4-week periods separated by a 4-week washout in a randomised cross-over design. Stool and rectal biopsy samples were collected for biochemical, microbial and immunohistochemical analyses at baseline and at the end of each 4-week intervention period. The HRM diet increased rectal O(6)MeG adducts relative to its baseline by 21% (P < 0.01), whereas the addition of HAMSB to the HRM diet prevented this increase. Epithelial proliferation increased with both the HRM (P < 0.001) and HRM + HAMSB (P < 0.05) diets when compared with their respective baseline levels, but was lower following the HRM + HAMSB diet compared with the HRM diet (P < 0.05). Relative to its baseline, the HRM + HAMSB diet increased the excretion of SCFA by over 20% (P < 0.05) and increased the absolute abundances of the Clostridium coccoides group (P < 0.05), the Clostridium leptum group (P < 0.05), Lactobacillus spp. (P < 0.01), Parabacteroides distasonis (P < 0.001) and Ruminococcus bromii (P < 0.05), but lowered Ruminococcus torques (P < 0.05) and the proportions of Ruminococcus gnavus, Ruminococcus torques and Escherichia coli (P < 0.01). HRM consumption could increase the risk of CRC through increased formation of colorectal epithelial O(6)MeG adducts. HAMSB consumption prevented red meat-induced adduct formation, which may be associated with increased stool SCFA levels and/or changes in the microbiota composition.


Asunto(s)
Desoxiguanosina/análogos & derivados , Dieta , Carne/efectos adversos , Almidón/química , Amilosa/química , Animales , Bacteroides/aislamiento & purificación , Bovinos , Clostridium/aislamiento & purificación , Colon/microbiología , Culinaria , Estudios Cruzados , Aductos de ADN , Desoxiguanosina/química , Registros de Dieta , Método Doble Ciego , Ingestión de Energía , Escherichia coli/aislamiento & purificación , Heces/química , Heces/microbiología , Femenino , Humanos , Lactobacillus/aislamiento & purificación , Masculino , Microbiota , Persona de Mediana Edad , Ruminococcus/aislamiento & purificación , Zea mays/química
10.
Cancer Prev Res (Phila) ; 7(8): 786-95, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25092886

RESUMEN

High red meat (HRM) intake is associated with increased colorectal cancer risk, while resistant starch is probably protective. Resistant starch fermentation produces butyrate, which can alter microRNA (miRNA) levels in colorectal cancer cells in vitro; effects of red meat and resistant starch on miRNA expression in vivo were unknown. This study examined whether a HRM diet altered miRNA expression in rectal mucosa tissue of healthy volunteers, and if supplementation with butyrylated resistant starch (HRM+HAMSB) modified this response. In a randomized cross-over design, 23 volunteers undertook four 4-week dietary interventions; an HRM diet (300 g/day lean red meat) and an HRM+HAMSB diet (HRM with 40 g/day butyrylated high amylose maize starch), preceded by an entry diet and separated by a washout. Fecal butyrate increased with the HRM+HAMSB diet. Levels of oncogenic mature miRNAs, including miR17-92 cluster miRNAs and miR21, increased in the rectal mucosa with the HRM diet, whereas the HRM+HAMSB diet restored miR17-92 miRNAs, but not miR21, to baseline levels. Elevated miR17-92 and miR21 in the HRM diet corresponded with increased cell proliferation, and a decrease in miR17-92 target gene transcript levels, including CDKN1A. The oncogenic miR17-92 cluster is differentially regulated by dietary factors that increase or decrease risk for colorectal cancer, and this may explain, at least in part, the respective risk profiles of HRM and resistant starch. These findings support increased resistant starch consumption as a means of reducing risk associated with an HRM diet.


Asunto(s)
Dieta , Regulación Neoplásica de la Expresión Génica , Mucosa Intestinal/metabolismo , Intestinos/microbiología , MicroARNs/metabolismo , Neoplasias del Recto/metabolismo , Anciano , Amilosa/química , Animales , Bebidas , Biopsia , Proliferación Celular , Citrus , Análisis por Conglomerados , Estudios Cruzados , Femenino , Perfilación de la Expresión Génica , Humanos , Masculino , Carne , Persona de Mediana Edad , Leche , Familia de Multigenes , ARN Largo no Codificante , Almidón , Zea mays
11.
Mol Nutr Food Res ; 58(3): 550-8, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24115497

RESUMEN

SCOPE: Red meat is considered a risk factor for colorectal cancer (CRC). Heme is considered to promote colonic hyperproliferation and cell damage. Resistant starch (RS) is a food that ferments in the colon with studies demonstrating protective effects against CRC. By utilizing the western diet model of spontaneous CRC, we determined if feeding heme (as hemin chloride) equivalent to a high red meat diet would increase colonic DNA adducts and CRC and whether RS could abrogate such effects. METHODS AND RESULTS: Four groups of mice: control, heme, RS and heme + RS were fed diets for 1 or 18 months. Colons were analyzed for apoptosis, proliferation, DNA adducts "8-hydroxy-2-deoxyguanosine" and "O(6) -methyl-2-deoxyguanosine" (O(6) MeG), and neoplasms. In the short term, heme increased cell proliferation (p < 0.05). Changes from 1 to 18 months showed increased cell proliferation (p < 0.01) and 8-hydroxy-2-deoxyguanosine adducts (p < 0.05) in all groups, but only heme-fed mice showed reduced apoptosis (p < 0.01) and increased O(6) MeG adducts (p < 0.01). The incidence of colon neoplasms was not different between any interventions. CONCLUSION: We identified heme to increase proliferation in the short term, inhibit apoptosis over the long term, and increase O(6) MeG adducts in the colon over time although these changes did not affect colonic neoplasms within this mouse model.


Asunto(s)
Neoplasias del Colon/etiología , Aductos de ADN/metabolismo , Dieta Occidental/efectos adversos , Hemo/efectos adversos , Animales , Peso Corporal/efectos de los fármacos , Neoplasias del Colon/patología , Neoplasias Colorrectales/etiología , Heces , Humanos , Masculino , Ratones Endogámicos C57BL , Mutágenos/metabolismo , Almidón/farmacología
12.
J Nutrigenet Nutrigenomics ; 7(4-6): 299-313, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-26022687

RESUMEN

Red meat may increase promutagenic lesions in the colon. Resistant starch (RS) can reduce these lesions and chemically induced colon tumours in rodents. Msh2 is a mismatch repair (MMR) protein, recognising unrepaired promutagenic adducts for removal. We determined if red meat and/or RS modulated DNA adducts or oncogenesis in Msh2-deficient mice. A total of 100 Msh2-/- and 60 wild-type mice consumed 1 of 4 diets for 6 months: control, RS, red meat and red meat+RS. Survival time, aberrant crypt foci (ACF), colon and small intestinal tumours, lymphoma, colonic O6-methyl-2-deoxyguanosine (O6MeG) adducts, methylguanine methyltransferase (MGMT) and cell proliferation were examined. In Msh2-/- mice, red meat enhanced survival compared to control (p<0.01) and lowered total tumour burden compared to RS (p<0.167). Msh2-/- mice had more ACF than wild-type mice (p<0.014), but no colon tumours developed. Msh2-/- increased cell proliferation (p<0.001), lowered DNA O6MeG adducts (p<0.143) and enhanced MGMT protein levels (p<0.001) compared to wild-type mice, with RS supplementation also protecting against DNA adducts (p<0.01). No link between red meat-induced promutagenic adducts and risk for colorectal cancer was observed after 6 months' feeding. Colonic epithelial changes after red meat and RS consumption with MMR deficiency will differ from normal epithelial cells.


Asunto(s)
Aductos de ADN/biosíntesis , Metilasas de Modificación del ADN/metabolismo , Enzimas Reparadoras del ADN/metabolismo , Neoplasias Intestinales/etiología , Linfoma/etiología , Proteína 2 Homóloga a MutS/deficiencia , Carne Roja , Almidón/administración & dosificación , Neoplasias del Timo/etiología , Proteínas Supresoras de Tumor/metabolismo , Animales , Anticarcinógenos/administración & dosificación , Reparación de la Incompatibilidad de ADN , Femenino , Neoplasias Intestinales/patología , Neoplasias Intestinales/prevención & control , Linfoma/patología , Linfoma/prevención & control , Masculino , Ratones , Ratones de la Cepa 129 , Ratones Endogámicos C57BL , Ratones Noqueados , Proteína 2 Homóloga a MutS/genética , Mutágenos/metabolismo , Nutrigenómica , Carne Roja/efectos adversos , Factores de Riesgo , Neoplasias del Timo/patología , Neoplasias del Timo/prevención & control
13.
Mar Drugs ; 12(1): 17-35, 2013 Dec 24.
Artículo en Inglés | MEDLINE | ID: mdl-24368567

RESUMEN

Muricid molluscs are a natural source of brominated isatin with anticancer activity. The aim of this study was to examine the safety and efficacy of synthetic 6-bromoisatin for reducing the risk of early stage colorectal tumor formation. The purity of 6-bromoisatin was confirmed by 1H NMR spectroscopy, then tested for in vitro and in vivo anticancer activity. A mouse model for colorectal cancer was utilized whereby colonic apoptosis and cell proliferation was measured 6 h after azoxymethane treatment by hematoxylin and immunohistochemical staining. Liver enzymes and other biochemistry parameters were measured in plasma and haematological assessment of the blood was conducted to assess potential toxic side-effects. 6-Bromoisatin inhibited proliferation of HT29 cells at IC50 223 µM (0.05 mg/mL) and induced apoptosis without increasing caspase 3/7 activity. In vivo 6-bromoisatin (0.05 mg/g) was found to significantly enhance the apoptotic index (p≤0.001) and reduced cell proliferation (p≤0.01) in the distal colon. There were no significant effects on mouse body weight, liver enzymes, biochemical factors or blood cells. However, 6-bromoisatin caused a decrease in the plasma level of potassium, suggesting a diuretic effect. In conclusion this study supports 6-bromoisatin in Muricidae extracts as a promising lead for prevention of colorectal cancer.


Asunto(s)
Antineoplásicos , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Neoplasias Colorrectales/inducido químicamente , Hidrocarburos Bromados/farmacología , Isatina/análogos & derivados , Caracoles/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Caspasas/metabolismo , Línea Celular Tumoral , Tamaño de la Célula/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Colon/patología , Neoplasias Colorrectales/patología , Ensayos de Selección de Medicamentos Antitumorales , Células HT29 , Humanos , Hidrocarburos Bromados/aislamiento & purificación , Inmunohistoquímica , Isatina/aislamiento & purificación , Isatina/farmacología , Antígeno Ki-67/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , Espectroscopía de Resonancia Magnética , Potasio/sangre , Caracoles/química
14.
Mutat Res Genet Toxicol Environ Mutagen ; 758(1-2): 80-6, 2013 Dec 12.
Artículo en Inglés | MEDLINE | ID: mdl-24140386

RESUMEN

Azoxymethane (AOM) is an alkylating agent that generates mutagenic and carcinogenic O(6)-methylguanine (O(6)meG) adducts in DNA. O(6)meG has been detected in human colonic DNA; hence, understanding the innate cellular events occurring in response to the formation of O(6)meG is important in developing preventive strategies for colorectal cancer. We explored the time-course, dose-response, and kinetics of O(6)meG formation and its removal by the DNA repair protein, O(6)-methylguanine DNA methyltransferase (MGMT), and apoptosis. In rats given AOM (10 mg/kg), the formation of O(6)meG occurs within 2 h of exposure, accompanied by rapid depletion of MGMT activity and followed by the induction of an acute apoptotic response that peaks at 6-8 h. MGMT repair and apoptosis are dependent on AOM dose and O(6)meG load. Apoptosis is initiated only when a high O(6)meG load is present and MGMT activity is fully depleted. AOM, 10 mg/kg, overwhelms MGMT repair for about 96 h and renewed MGMT activity is only observed once O(6)meG is no longer detectable. A threshold for apoptosis is observed at 6 h after 6 mg/kg AOM, when a high O(6)meG persists and MGMT activity is very low. These data suggest that apoptosis is probably triggered by O(6)meG, but only once the capacity of MGMT to repair O(6)meG is exhausted. In the colonic epithelium, apoptosis may be complementary to MGMT, in terms of minimising potentially mutagenic events and maintaining a healthy genome.


Asunto(s)
Apoptosis/efectos de los fármacos , Azoximetano/toxicidad , Colon/efectos de los fármacos , Guanina/análogos & derivados , O(6)-Metilguanina-ADN Metiltransferasa/metabolismo , Animales , Colon/citología , Colon/metabolismo , Guanina/metabolismo , Ratas
15.
Anticancer Res ; 33(9): 3581-8, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24023283

RESUMEN

The protection against colorectal cancer (CRC) by non-steroidal anti-inflammatory drugs (NSAIDs) is in part dependent on inhibition of cyclooxygenase (COX). We compared the efficacy of the non-COX-inhibiting R-flurbiprofen (R-FB) with COX-inhibiting sulindac and racemic flurbiprofen (Rac-FB), and determined their effects on apoptosis, in an azoxymethane (AOM)-induced rat CRC model. In experiment 1, groups of rats were given a daily drug gavage (R-FB 30 mg/kg, Rac-FB 10 mg/kg and Sulindac 20 mg/kg) for one week, followed by AOM treatment and were sacrificed eight hours later, colons were examined for apoptosis and cell proliferation. In experiment 2, groups of rats were given two AOM treatments, followed by a daily drug gavage until they were sacrificed ten weeks later, and colons were examined for aberrant crypt foci (ACF) and prostaglandin E2 production. All drugs significantly enhanced apoptosis and inhibited ACF, irrespective of their COX-inhibiting potency (p<0.01), but sulindac was more potent in inhibition of large ACF, p<0.05. COX-inhibiting sulindac achieved the greatest protective effect. The greater safety profile of Rac-FB should provide an advantage for chemoprevention.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Apoptosis/efectos de los fármacos , Neoplasias Colorrectales/patología , Inhibidores de la Ciclooxigenasa/farmacología , Animales , Azoximetano/toxicidad , Neoplasias Colorrectales/inducido químicamente , Neoplasias Colorrectales/prevención & control , Modelos Animales de Enfermedad , Flurbiprofeno/farmacología , Masculino , Lesiones Precancerosas/inducido químicamente , Lesiones Precancerosas/patología , Lesiones Precancerosas/prevención & control , Ratas , Ratas Sprague-Dawley , Sulindac/farmacología
16.
Artículo en Inglés | MEDLINE | ID: mdl-23690858

RESUMEN

Marine molluscs from the family Muricidae are under development as a potential medicinal food for the prevention of colon cancer and treatment of gynaecological cancers. Here we report the outcome of the first in vivo toxicity assessment on an anticancer extract from a muricid mollusc containing brominated indole derivatives. Mice received the concentrated lipophilic extract by daily oral gavage over a two-week period. Mortality or clinical toxicity symptoms resulting from the extract were not detected during the trial, and there was no difference in the body weight of treated and control mice at the end of the trial. Histological analysis revealed some evidence for mild, idiosyncratic effects on the gastrointestinal tract and liver, including necrosis, fatty change, and inflammation in a small proportion (<40%) of mice. This is likely to result from first-pass hepatic metabolism of tyrindoxyl sulphate combined with second-pass metabolism of indoles. Overall however, oral administration of muricid extract containing brominated indoles does not result in severe clinical toxicity.

17.
PLoS One ; 8(5): e64362, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23717604

RESUMEN

Dietary supplementation of selenium and green tea holds promise in cancer prevention. In this study, we evaluated the efficacies of selenium and green tea administered individually and in combination against colorectal cancer in an azoxymethane (AOM)-induced rat colonic carcinogenesis model and determined the underlying mechanisms of the protection. Four-week old Sprague-Dawley male rats were fed with diets containing 0.5% green tea extract, 1 ppm selenium as selenium-enriched milk protein, or combination of 1 ppm selenium and 0.5% green tea extract. Animals received 2 AOM (15 mg/kg) treatments to induce colonic oncogenesis. Rats were killed 8 or 30 wk later after the last AOM to examine the effect of dietary intervention on aberrant crypt foci (ACF) formation or tumor development. On sacrifice, colons were examined for ACF and tumors, the mRNA levels of SFRP5 and Cyclin D1, and the proteins levels of ß-catenin, COX-2, Ki-67, DNMT1 and acetyl histone H3. The combination of selenium and green tea resulted in a significant additive inhibition of large ACF formation, this effect was greater than either selenium or green tea alone, P<0.01; the combination also had a significant additive inhibition effect on all tumor endpoints, the effect of the combination diet on tumor incidence, multiplicity and size was greater than selenium or green tea alone, P<0.01. Rats fed the combination diet showed marked reduction of DNMT1 expression and induction of histone H3 acetylation, which were accompanied by restoration of SFRP5 mRNA in normal-appearing colonic crypts. The combination diet also significantly reduced ß-catenin nuclear translocation, Cyclin D1 expression and cell proliferation. These data show, for the first time, that combination of selenium and green tea is more effective in suppressing colorectal oncogenesis than either agent alone. The preventive effect is associated with regulation of genetic and epigenetic biomarkers implicated in colonic carcinogenesis.


Asunto(s)
Anticarcinógenos/administración & dosificación , Neoplasias Colorrectales/prevención & control , Epigénesis Genética/efectos de los fármacos , Extractos Vegetales/administración & dosificación , Selenio/administración & dosificación , Acetilación , Administración Oral , Animales , Anticarcinógenos/farmacología , Azoximetano , Proliferación Celular , Quimioprevención , Neoplasias Colorrectales/inducido químicamente , Neoplasias Colorrectales/genética , Neoplasias Colorrectales/patología , Ciclooxigenasa 2/metabolismo , ADN (Citosina-5-)-Metiltransferasa 1 , ADN (Citosina-5-)-Metiltransferasas/metabolismo , Suplementos Dietéticos , Marcadores Genéticos , Histonas/metabolismo , Antígeno Ki-67/metabolismo , Masculino , Extractos Vegetales/farmacología , Procesamiento Proteico-Postraduccional , Ratas , Ratas Sprague-Dawley , Selenio/farmacología , Carga Tumoral
18.
Mol Carcinog ; 52(6): 459-74, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22308110

RESUMEN

Diet-derived butyrate, a histone deacetylase inhibitor (HDI), decreases proliferation and increases apoptosis in colorectal cancer (CRC) cells via epigenetic changes in gene expression. Other HDIs such as suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA) have similar effects. This study examined the role of microRNAs (miRNAs) in mediating the chemo-protective effects of HDIs, and explored functions of the oncogenic miR-17-92 cluster. The dysregulated miRNA expression observed in HT29 and HCT116 CRC cells could be epigenetically altered by butyrate, SAHA and TSA. These HDIs decreased expression of miR-17-92 cluster miRNAs (P < 0.05), with a corresponding increase in miR-17-92 target genes, including PTEN, BCL2L11, and CDKN1A (P < 0.05). The decrease in miR-17-92 expression may be partly responsible for the anti-proliferative effects of HDIs, with introduction of miR-17-92 cluster miRNA mimics reversing this effect and decreasing levels of PTEN, BCL2L11, and CDKN1A (P < 0.05). The growth effects of HDIs may be mediated by changes in miRNA activity, with down-regulation of the miR-17-92 cluster a plausible mechanism to explain some of the chemo-protective effects of HDIs. Of the miR-17-92 cluster miRNAs, miR-19a and miR-19b were primarily responsible for promoting proliferation, while miR-18a acted in opposition to other cluster members to decrease growth. NEDD9 and CDK19 were identified as novel miR-18a targets and were shown to be pro-proliferative genes, with RNA interference of their transcripts decreasing proliferation in CRC cells. This is the first study to identify competing roles for miR-17-92 cluster members, in the context of HDI-induced changes in CRC cells.


Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Ácido Butírico/farmacología , Neoplasias Colorrectales/tratamiento farmacológico , Inhibidores de Histona Desacetilasas/farmacología , Ácidos Hidroxámicos/farmacología , MicroARNs/genética , Proteínas Adaptadoras Transductoras de Señales/genética , Adenocarcinoma/genética , Proteínas Reguladoras de la Apoptosis/genética , Proteína 11 Similar a Bcl2 , Neoplasias Colorrectales/genética , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Regulación hacia Abajo/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Células HCT116 , Células HT29 , Humanos , Proteínas de la Membrana/genética , Fosfohidrolasa PTEN/genética , Fosfoproteínas/genética , Proteínas Proto-Oncogénicas/genética , ARN Largo no Codificante , ARN Mensajero/genética , Transfección , Vorinostat
19.
Cancer Prev Res (Phila) ; 4(11): 1920-8, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21885815

RESUMEN

Population studies have shown that high red meat intake may increase colorectal cancer risk. Our aim was to examine the effect of different amounts and sources of dietary protein on induction of the promutagenic adduct O(6)-methyl-2-deoxyguanosine (O(6)MeG) in colonocytes, to relate these to markers of large bowel protein fermentation and ascertain whether increasing colonic carbohydrate fermentation modified these effects. Mice (n = 72) were fed 15% or 30% protein as casein or red meat or 30% protein with 10% high amylose maize starch as the source of resistant starch. Genetic damage in distal colonocytes was detected by immunohistochemical staining for O(6)MeG and apoptosis. Feces were collected for measurement of pH, ammonia, phenols, p-cresol, and short-chain fatty acids (SCFA). O(6)MeG and fecal p-cresol concentrations were significantly higher with red meat than with casein (P < 0.018), with adducts accumulating in cells at the crypt apex. DNA adducts (P < 0.01) and apoptosis (P < 0.001) were lower and protein fermentation products (fecal ammonia, P < 0.05; phenol, P < 0.0001) higher in mice fed resistant starch. Fecal SCFA levels were also higher in mice fed resistant starch (P < 0.0001). This is the first demonstration that high protein diets increase promutagenic adducts (O(6)MeG) in the colon and dietary protein type seems to be the critical factor. The delivery of fermentable carbohydrate to the colon (as resistant starch) seems to switch from fermentation of protein to that of carbohydrate and a reduction in adduct formation, supporting previous observations that dietary resistant starch opposes the mutagenic effects of dietary red meat.


Asunto(s)
Colon/efectos de los fármacos , Aductos de ADN/efectos de los fármacos , Desoxiguanosina/análogos & derivados , Carne/toxicidad , Mutágenos/toxicidad , Almidón/farmacología , Animales , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Desoxiguanosina/toxicidad , Carbohidratos de la Dieta/farmacología , Proteínas en la Dieta/farmacología , Heces/química , Fermentación , Intestino Grueso/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL
20.
Br J Nutr ; 106(4): 572-82, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21450115

RESUMEN

Certain forms of dietary Se may have advantages for improving human Se status and regulating the risk for disease, such as cancers, including colorectal cancer (CRC). The present study compared the effects of a Se-enriched milk protein (dairy-Se) with a Se-rich yeast (yeast-Se) on plasma Se levels and rectal selenoprotein gene expression since we reasoned that if these genes were not regulated, there was little potential for regulating the risk for CRC in this organ. A total of twenty-three healthy volunteers with plasma Se in the lower half of the population range were supplemented with dairy-Se (150 µg/d) or yeast-Se (150 µg/d) for 6 weeks, followed by 6 weeks of washout period. Blood was sampled every 2 weeks, and rectal biopsies were obtained before and after Se supplementation and after the washout period. Plasma Se levels and glutathione peroxidase (GPx) activity, and rectal mRNA of selenoprotein P (SeP), cytosolic GPx-1 (GPx-1), gastrointestinal GPx-2 (GPx-2) and thioredoxin reductase-1 (TrxR-1) were measured. Plasma Se levels increased rapidly in both Se groups (P < 0·001); plasma GPx activity was not significantly changed. Rectal SeP mRNA increased at 6 weeks compared with baseline in both Se groups (P < 0·05); only dairy-Se resulted in a sustained elevation of SeP after the washout period (P < 0·05). Rectal GPx-1 and GPx-2 mRNA were higher with dairy-Se (P < 0·05) than with yeast-Se at 6 weeks. In conclusion, three rectal selenoprotein mRNA were differentially regulated by dairy-Se and yeast-Se. Changes in rectal selenoproteins are not predicted by changes in plasma Se; dairy-Se effectively regulates the expression of several rectal selenoproteins of relevance to the risk for CRC.


Asunto(s)
Regulación de la Expresión Génica , Proteínas de la Leche/uso terapéutico , Recto/metabolismo , Selenio/deficiencia , Selenio/uso terapéutico , Selenoproteínas/metabolismo , Levadura Seca/uso terapéutico , Anciano , Australia/epidemiología , Biopsia , Neoplasias Colorrectales/epidemiología , Suplementos Dietéticos , Método Doble Ciego , Femenino , Glutatión Peroxidasa/sangre , Glutatión Peroxidasa/genética , Glutatión Peroxidasa/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Proteínas de la Leche/química , ARN Mensajero/metabolismo , Recto/patología , Factores de Riesgo , Selenio/sangre , Selenoproteína P/genética , Selenoproteína P/metabolismo , Selenoproteínas/genética , Índice de Severidad de la Enfermedad , Levadura Seca/química , Glutatión Peroxidasa GPX1
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA